24 completed, 1 recruiting, 1 terminated, 1 unknown. 11 Phase 3, 7 Phase 2, 7 Phase 4, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 11 | Completed 10, Unknown 1 |
| Phase 2 | 7 | Completed 5, Recruiting 1, Terminated 1 |
| Phase 4 | 7 | Completed 7 |
| Phase 1 | 1 | Completed 1 |
Follow Prevenar 13: new trials by email Literature Review of Prevenar 13 trials Research Report on Prevenar 13
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants Low dose of iNTS-TCV, Full dose of iNTS-TCV, TYPHIBEV - Salmonella Infections | Phase 2 | Recruiting | GlaxoSmithKline | 537 | 2026-04-01 | 2026-04-20 |
| Phase III Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine (Multivalent Conjugate) in Infants 13-valent pneumococcal conjugate vaccine (multivalent conjugate), Prevenar 13 - Streptococcus Pneumoniae Infection | Phase 3 | Unknown | Fosun Adgenvax Biopharmaceutical Co.,Ltd. | 1800 | 2022-11-04 | 2024-10-01 |
| A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and Toddlers DTPa-HBV-IPV/Hib, DTaP5-HBV-IPV-Hib, Pneumococcal 13-valent conjugate vaccine - Diphtheria | Phase 4 | Completed | GlaxoSmithKline | 500 | 2021-05-26 | 2024-08-27 |
| Study of 10-valent Pneumococcal Conjugate Vaccine (Pneumosil) Administered in a 2+1 Schedule to Healthy Infants Pneumosil, Prevenar 13, Synflorix - Pneumonia, Pneumococcal | Phase 3 | Completed | PATH | 660 | 2019-07-18 | 2022-04-20 |
| Pneumococcal Vaccination to Accelerate Immune Recovery in Sepsis Survivors Prevenar 13, Sodium Chloride 0.9% - Sepsis | Phase 4 | Completed | Guy's and St Thomas' NHS Foundation Trust | 214 | 2018-08-02 | 2023-11-24 |
| Sequential Versus Simultaneous Pneumococcal Vaccination in Elderly: Immunological Memory and Antibody Levels PCV13, PPV23 - Pneumococcal Infections | Phase 4 | Completed | Jena University Hospital | 123 | 2017-10-18 | 2023-12-01 |
| This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine Rotarix, Pediarix, Hiberix - Rotavirus Infection, Rotavirus Vaccines | Phase 3 | Completed | GlaxoSmithKline | 1280 | 2017-09-14 | 2020-12-29 |
| Reduced PCV Dosing Schedules in South African Infants Pneumococcal conjugate vaccine (PCV10 ) 1+1, 6 weeks, Pneumococcal conjugate vaccine (PCV10 ) 1+1, 14 weeks, Pneumococcal conjugate vaccine (PCV10 ) 2+1 - Pneumonia, Meningitis | Phase 3 | Completed | University of Witwatersrand, South Africa | 600 | 2017-01-09 | 2019-12-09 |
| Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease 13-valent pneumococcal conjugate vaccine, 23-valent pneumococcal polysaccharide vaccine - Rheumatoid Arthritis, Systemic Lupus | Phase 4 | Completed | Region Skane | 300 | 2016-06-14 | 2023-03-29 |
| Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for CIBD Prevenar 13, Pneumo 23 - Infections, Pneumococcal, Bowel Diseases, Inflammatory | Phase 2 | Terminated | Centre Hospitalier Universitaire de Saint Etienne | 104 | 2015-04-13 | 2023-06-15 |
| Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants SIILPCV10, Pneumovax 23, Prevenar 13 - Pneumococcal Disease | Phase 1 / Phase 2 | Completed | PATH | 346 | 2015-01-12 | 2019-08-02 |
| Community Acquired Pneumonia: Outcome, Quality of Life and Immune Status Prevnar 13 - Pneumonia, Streptococcus Pneumoniae | Phase 4 | Completed | St. Antonius Hospital | 60 | 2014-04-01 | 2014-12-23 |
| VACcination In Methotrexate Treated Rheumatoid Arthritis Patients Prevenar 13, Pneumo23 / Pneumovax, Methotrexate - Immediate - Rheumatoid Arthritis | Phase 3 | Completed | University Hospital, Montpellier | 276 | 2013-09-27 | 2020-08-03 |
| Pneumococcal Vaccine in Untreated CLL Patients Prevenar 13, Pneumovax - Chronic Lymphocytic Leukemia | Phase 3 | Completed | Karolinska University Hospital | 134 | 2013-08-01 | 2016-01-15 |
| Pneumococcal Vaccination of Crohn Patients Prevenar 13, Pneumovax - Crohns Disease | Phase 4 | Completed | Statens Serum Institut | 151 | 2013-07-01 | 2015-02-10 |
| Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination Hexavalent vaccine, NeisVac-C, Prevenar 13 - Neisseria Meningitidis, Bacterial Infections | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 350 | 2013-04-01 | 2017-09-11 |
| 13 Valent Pneumococcal Conjugate Vaccine in Chronic Dialysis Patients PPV23 vaccination or PCV13 vaccination - Chronic Kidney Failure | Phase 4 | Completed | AZ Sint-Jan AV | 154 | 2013-02-01 | 2015-07-08 |
| Pneumococcal Adult Kinetics Study - Understanding the B Cell Response to Pneumococcal Vaccines Prevenar 13, Pneumovax II - Pneumococcal Disease | Phase 3 | Completed | University of Oxford | 4 | 2012-01-01 | 2015-11-09 |
| Safety Surveillance of Pneumococcal 13-valent Conjugate Vaccine Among Filipinos Prevenar 13 - Pneumococcal Disease | Completed | Pfizer | 3006 | 2011-12-01 | 2017-01-30 | |
| Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) Infanrix hexa, Prevenar 13, GSK217744 - Acellular Pertussis, Hepatitis B | Phase 2 | Completed | GlaxoSmithKline | 657 | 2011-10-14 | 2020-07-17 |
Showing 20 of 27. Sign in to see all of them.
Pneumococcal Infections (7) · Haemophilus Infections (4) · Diphtheria (3) · Hepatitis B (3) · Tetanus (3) · Typhoid Fever (3) · Arthritis, Rheumatoid (2) · Bacterial Infections (2) · Pneumonia (2) · Poliomyelitis (2) · Virus Diseases (2) · Crohn Disease (1) · Inflammatory Bowel Diseases (1) · Influenza, Human (1) · Kidney Failure, Chronic (1)
GlaxoSmithKline (6) · Pfizer (3) · Novartis (2) · PATH (2) · AZ Sint-Jan AV (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · Fosun Adgenvax Biopharmaceutical Co.,Ltd. (1) · Guy's and St Thomas' NHS Foundation Trust (1) · Jena University Hospital (1) · Karolinska University Hospital (1) · MCM Vaccines B.V. (1) · Region Skane (1) · Sanofi Pasteur, a Sanofi Company (1) · St. Antonius Hospital (1) · Statens Serum Institut (1)
Germany (3) · Philippines (3) · Poland (3) · Spain (3) · The Gambia (3) · United Kingdom (3) · Belgium (2) · Czechia (2) · Dominican Republic (2) · Finland (2) · France (2) · India (2) · Sweden (2) · Bangladesh (1) · China (1)
Andreas M Petersen, MD (1) · Andrew J Pollard, BSc MBBS PhD MRCP FRCPCH (1) · Bart JM Vlaminckx, Phd (1) · Ed Clarke, MB ChB, PhD (1) · Ed Clarke, MD PhD (1) · Eva Kimby, Professor (1) · Ger T Rijkers, Prof (1) · Gertjan H Wagenvoort, MD (1) · Jehns Martineus, MD (1) · Manu Shankar-Hari, PhD (1)
PMID 24290843, PMID 26275480, PMID 27846055, PMID 27939054, PMID 28340322, PMID 28802755, PMID 30325891, PMID 30471953, PMID 31290715, PMID 31306399, PMID 31725115, PMID 31843266, PMID 32087733, PMID 32857992, PMID 35083365, PMID 36638819, PMID 36934731, PMID 38637212, PMID 39865559, PMID 40396505, PMID 40749694, PMID 42172618, PMID 42585292
2009 (1), 2016 (1), 2017 (1), 2019 (1)